Evolocumab

Evolocumab is a monoclonal antibody used to lower low-density lipoprotein cholesterol (LDL-C) in the blood. It works by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), which enhances the liver's ability to remove LDL-C from the bloodstream. It is used as an adjunct to diet, statins, or other lipid-lowering therapies in patients who require additional LDL-C reduction.

Indications

- Hypercholesterolemia (Primary and familial heterozygous) - Homozygous familial hypercholesterolemia - Patients with atherosclerotic cardiovascular disease who require additional LDL-C lowering

Dosage

- Typical dose: 140 mg every 2 weeks or 420 mg once monthly via subcutaneous injection - Dosage may be adjusted based on LDL-C response and patient requirements - Should be administered under proper guidance and stored according to manufacturer instructions

Contra-Indications

- Hypersensitivity to Evolocumab or any of its components - Severe allergic reactions to monoclonal antibodies

Special Precautions

- Monitor for signs of allergic reactions during and after administration - Use caution in patients with active infections or immunocompromised conditions - Safety in pregnancy and lactation has not been fully established; consult a physician - May require monitoring of liver function in patients on concurrent lipid-lowering therapy

Side Effects

- Common: Nasopharyngitis, upper respiratory tract infections, influenza, injection site reactions - Less common: Back pain, myalgia, dizziness - Rare: Serious hypersensitivity reactions, including anaphylaxis

Drug Interactions

- Evolocumab has a low potential for drug-drug interactions - Concomitant use with statins or other lipid-lowering therapies is generally safe and may be more effective - Always inform the physician about all medications being taken